Evelyn Partners’s AbbVie ABBV Stock Holding History

Evelyn Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.47M	Buy	+9,801	New	+$2.11M	0.01%	131

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Evelyn Partners's ABBV Position: Q2 2026 in Review

Evelyn Partners opened a new position in AbbVie (ABBV) in Q2 2026: 9,801 shares worth $2.47M. The stake represents 0.01% of the portfolio and ranks #131 among its holdings.

4,063 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Evelyn Partners held 9,801 shares of AbbVie worth $2.47M as of Q2 2026.
AbbVie was a new Evelyn Partners position in Q2 2026.
AbbVie made up 0.01% of Evelyn Partners's portfolio in Q2 2026, its #131 holding.
4,063 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Evelyn Partners's 13F filing for Q2 2026, filed 7 Aug 2026.